A Atherosclerosis-related cardiovascular disease remains an important cause of morbidity and mortality in renal transplant patients. We assessed the efficacy and safety of the newer synthetic HMG-CoA reductase inhibitor, fluvastatin, in 12 renal transplant patients who remained hypercholesterolemic, despite having been on the American Heart Association (AHA) Step I diet for 6 weeks. At 8 weeks, compared to the control phase, fluvastatin therapy, 20 mg/day, reduced the total cholesterol (TC) from 321 ± 57 [± SD] to 301 ± 123 mg/dl (p=0.3); low-density lipoprotein cholesterol (LDL-C), from 209 ± 56 to 176 ± 81 mg/dl (p=0.2); and the triglyceride (TG) levels from 343 ± 119 to 277 ± 117 mg/dl (p=0.06); all these changes were statistically insignificant. However, the therapy significantly increased the high-density lipoprotein cholesterol (HDL-C) from 37 ± 11 to 46 ± 13 mg/dl (p=0.006). During this short-term treatment period no adverse biochemical effects were noted with the therapy.
BittarA.E., RatcliffeP.J., RichardsonA.J.. The prevalence of hyperlipidemia in renal transplant recipients.Transplantation1990; 50: 987–92.
2.
CasarettoA., MarchioroT.L., GoldsmithR., BagdadeJ.D.. Hyperlipidemia after successful transplantation.Lancet1974; 1: 481–4.
3.
US Renal Data System: Causes of death.Am J Kidney Dis1994; 24: 88–95.
4.
Editorial: Hyperlipidemia after renal transplantation.Lancet1988; 1: 919–20.
5.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)JAMA1993; 269: 3015–23.
6.
LaRossaJ.C., HunninghakeD., BushD.. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute.Circulation1990; 81: 1721–33.
7.
Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: Reduction in the incidence of coronary heart disease.JAMA1984; 251: 351–64.
8.
CannerP.L., BergeK.G., WengerN.K.. For the coronary drug project research group. Fifteen-year mortality in coronary drug project patients: long term benefit with niacin.J Am Coll Cardiol1986; 8: 1245–55.
9.
Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study.The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.Am J Cardiology1995; 76: 485–91.
10.
BlankenhornD.M., NessimS.A., JohnsonR.L., SanmarcoM.E., AzenS.P., Cashen-HemphillL.. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA1987; 257: 3233–40.
11.
The lovastatin study group III.A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia.JAMA1988; 260: 359–66.
12.
BradfordR.H., ShearC.L., ChremosA.N.. Expanded clinical evaluation of lovastatin (EXCEL) study results.Arch Intern Med1991; 151: 43–9.
13.
MooreR.A., CallahanM.F., CodyM.. The effects of the American Heart Association step I diet on hyperlipidemia following renal transplantation.Transplantation1990; 49: 60–2.
14.
KasiskeB., TortoriceK.L., Heim-DuthoyK.L., GoryanceJ.M., RaoK.V.. Lovastatin treatment of hypercholesterolemia in renal transplant recipients.Transplantation1990; 49: 95–100.
15.
YoshimuraN., OkaT., OkamotoM., OshmoriY.. The effects of pravastatin on hyperlipidemia in renal transplant recipients.Transplantation1992; 53: 94–9.
16.
Martinez-HernandezB., PersaudJ.W., VargheseZ., MoorheadJ.F.. Low dose simvastatin is safe in hyperlipidemic transplant patients treated with cyclosporine.Nephrol Dial Trap1993; 8: 637–41.
17.
LalS.M., PetroskiG.F., HewettJ.E., Van StoneJ.C., RossG.Jr. Effects of nicotinic acid and lovastatin in renal transplant patients. A prospective, randomized, open labelled Crossover Trial.Am J Kidney Dis1995; 25: 616–22.
18.
LalS.M., TrivediH.S., Van StoneJ.C., RossG.Jr. Lipid lowering effects of AHA Step I and II diets in renal transplant patients. A prospective study.Int J Artif Organs1994; 17: 423–7.
19.
IllingworthD.R., ErkelensD.W., KellerU., ThompsonG.R., TikkanenM.J.. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.Lancet1994; 343: 1554–5.
20.
JacototB., BangaJ.D., PfisterP., MehraM.. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.Br J Clin Pharmacol1994; 38: 257–63.
21.
BangaJ.D., JacototB., PfisterP., MehraM.. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group.Am J Med1994; 96: 87–93.
22.
PetersT.K., MurattiE.N., MehraM.. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.Am J Med1994; 96: 79–83.
23.
DavidsonM.H.. Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety.Am J Med1994; 96: 41–4.
24.
FriedewaldW.T., LevyR.I., FredricksonD.S.. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem1972; 18: 499–502.
25.
AppelG.. Lipid abnormalities in renal disease.Kidney Int1991; 39: 169–83.
